Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Business
  • Published:

Merck opts for shake-up to clear drug pipeline

Nature volume 438, pages 1076–1077 (2005)Cite this article

The failure of the painkiller Vioxx and a lack of new products leaves the world's third-largest drug company in the lurch. Emma Marris reports.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Related links

Related links

Related links in Nature Research

Journal grows suspicious of Vioxx data

Painkiller verdict shows mistrust of Merck

Painkiller in the dock

NPG Drug Discovery portal

Related external links

Merck

Merck's stock info on NYSE

PubChem — Substance P

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merck opts for shake-up to clear drug pipeline. Nature 438, 1076–1077 (2005). https://doi.org/10.1038/4381076a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/4381076a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing